EXINI Diagnostics AB
EXINI’s heart-product fast growing on the Japanese market – hits 300 installed units
DGAP-News: EXINI Diagnostics AB 08.09.2014 / 08:50 --------------------------------------------------------------------- Lund, Sweden, 2014-09-08 08:50 CEST (GLOBE NEWSWIRE) -- Market penetration for the heart-product EXINI heart (cardioREPO in Japan) exceeds expectations. FUJIFILM RI Pharma Co. Ltd carries the exclusive rights for EXINI heart in Japan, and has over the past months installed 300 units of the software system cardioREPO in clinics throughout Japan. 'Japanese doctors show great interest in cardioREPO as we introduce it to them. The unique features and advanced functions have been developed over the past two years and stems from extensive input from Japanese physicians. The launch of cardioREPO in Japan provide both doctors and patients the possibility to benefit from this hard work', explains Takehiro Ishikawa, Product Manager, FUJIFILM RI Pharma. 'The collaboration with FUJIFILM RI Pharma is working well and the rate of installations continues to impress us', comments Magnus Aurell, CEO EXINI Diagnostics AB About EXINI heart (cardioREPO) - cardiology The product cardioREPO is an advanced customization of the diagnostic software system EXINI heart developed for the Japanese market, providing clinics and specialists with advanced information crucial in managing patients suffering from suspected or known ischemic heart conditions (e.g. Heart attacks or Angina). For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkommission AB acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX --------------------------------------------------------------------- 08.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden ISIN: SE0001810284 End of News DGAP News-Service --------------------------------------------------------------------- 285860 08.09.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden